Novlead Biotech

Novlead Biotech, established in April 2018 and headquartered in Nanjing, China, is a global leader in gas-based diagnosis and treatment for cardiopulmonary diseases. We specialize in the research, development, and application of inhaled nitric oxide (iNO) therapy, standing as one of the few companies worldwide with a comprehensive portfolio of NO therapeutic and diagnostic products. Leveraging our independently controlled platform for precise gas-liquid technology, we have built an end-to-end technical system encompassing NO generation, transmission, detection, storage, and clinical application. Our products and services cover the entire cycle of cardiopulmonary care—from ICU emergency care and hospitalization to outpatient visits and home management—making innovations in NO technology more convenient, accessible, and affordable for both patients and healthcare providers. Currently, our business spans over 800 hospitals across all 31 provinces in China, with commercial operations established in 10 countries and regions, including France and Hungary. The company has been recognized with numerous honors, such as National High-Tech Enterprise and Jiangsu Province’s Specialized, Refined, Differential, and Innovative SME. Driven by innovation and centered on patients, we continue to promote clinically validated NO therapies and cardiopulmonary diagnostic and treatment technologies from hospitals to broader clinical settings, injecting more possibilities into saving lives.